The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Gliclazide MR 30 mg prolonged-release tablets

30 milligram(s) Prolonged-release tablet

Brillpharma (Ireland) LimitedPA22749/006/001

Main Information

Trade NameGliclazide MR 30 mg prolonged-release tablets
Active SubstancesGliclazide
Strength30 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderBrillpharma (Ireland) Limited
Licence NumberPA22749/006/001

Group Information

ATC CodeA10BB Sulfonamides, urea derivatives
A10BB09 gliclazide

Status

Authorised/WithdrawnAuthorised
Licence Issued12/09/2014
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThe name Gliclazide MR 30mg prolonged-release tablets is a ‘registration’ name. It has been agreed subject to the following conditions: a) The MAH commits not to market the product using the ‘registration’ name. b) The MAH commits to change the ‘registration’ name to an invented name by variation prior to marketing in Ireland
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0086-033-050
Interchangeable List DocumentPDF of Interchangeable List
« Back